Tamir Biotechnology, Inc.

Tamir Biotechnology, Inc., a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company’s lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. Tamir Biotechnology also focuses on new drug application for unresectable malignant mesothelioma. In addition, it completed a Phase I clinical trial for the treatment of non-small cell lung cancer. The company was formerly known as Alfacell Corporation and changed its name to Tamir Biotechnology, Inc. in April 2010. Tamir Biotechnology, Inc. was founded in 1981 and is headquartered in Short Hills, New Jersey.